medigraphic.com
ISSN 0016-3813 (Impreso)

2019, Número 5

<< Anterior Siguiente >>

Gac Med Mex 2019; 155 (5)


Relación entre el índice lipoproteínas de baja densidad (LDL)/lipoproteínas de alta densidad (HDL) con enzimas antioxidantes y el índice oxLDL/HDL

Zamora-Ginez I, Baez-Duarte BG, Nieva-Vazquez A, García-Aragón KH, Monjaraz-Guzmán E, Mendoza-Carrera F, Meneses-Zamora P, Flores-Blanco CV, Luna-De Jesús K

Idioma: Español
Referencias bibliográficas: 39
Paginas: 487-492
Archivo PDF: 168.86 Kb.


RESUMEN

Introducción: El índice de lipoproteínas de baja densidad (LDL)/lipoproteínas de alta densidad (HDL) es un factor predictivo de aterosclerosis, la cual está asociada con modificaciones oxidativas. Objetivo: Evaluar la asociación del índice con marcadores de estrés oxidativo. Método: Se incluyeron 444 sujetos, caracterizados clínica, antropométrica y bioquímicamente; se cuantificó superóxido dismutasa, glutation peroxidasa 3 (GPx3), magnesio e índice LDL oxidadas (oxLDL/HDL). Resultados: La disminución en 1.014 unidades del índice LDL/HDL se asoció con aumento de 1 unidad/mL de superóxido dismutasa (p = 0.030) y la de 0.023 unidades con aumento de 1 nmol/minuto/mL de GPx3 (p ‹ 0.0005). El aumento en 1 unidad del índice se asoció con aumento de 0.831 unidades en el índice oxLDL/HDL (p ‹ 0.05). Después de controlar el efecto del sexo, edad, fumar, obesidad y resistencia a la insulina, la reducción de 0.001 por unidad del índice se asoció con aumento de 1 µg/g de magnesio en uñas (p = 0.020). Conclusiones: El índice LDL/HDL presenta relación inversa con el estado antioxidante y relación directa con el estado de oxidación, independientemente de otros factores de riesgo cardiovascular y de estrés oxidativo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Le NA. Lipoprotein-associated oxidative stress: a new twist to the postprandial hypothesis. Int J Mol Sci. 2014;16:401-419.

  2. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult tratment Panel III) final report. Circulation. 2002;106:3143-3421.

  3. Ruscica M, Botta M, Ferri N, Giorgio E, Macchi C, Franceschini G, et al. High density lipoproteins inhibit oxidative stress-induced prostate cancer cell proliferation. Sci Rep. 2018;8:2236.

  4. Pawlak K, Mysliwiec M, Pawlak D. Oxidized low-density lipoprotein (oxLDL) plasma levels and oxLDL to LDL ratio. Are they real oxidative stress markers in dialyzed patients? Life Sci. 2013;92:253-258.

  5. Linna M, Ahotupa M, Löppönen MK, Irjala K, Vasankari T. Circulating oxidised LDL lipids, when proportioned to HDL-c, emerged as a risk factor of all-cause mortality in a population-based survival study. Age Ageing. 2013;42:110-113.

  6. Anatoliotakis N, Deftereos S, Bouras G, Giannopoulos G, Tsounis D, Angelidis C, et al. Myeloperoxidase: expressing inflammation and oxidative stress in cardiovascular disease. Curr Top Med Chem. 2013; 13:115-138.

  7. Zheltova AA, Kharitonova MV, Iezhitsa IN, Spasov AA. Magnesium deficiency and oxidative stress: an update. Biomedicine (Taipei). 2016; 6:8-14.

  8. Rupérez AI, Gil A, Aguilera CM. Genetics of oxidative stress in obesity. Int J Mol Sci. 2014;15:3118-344.

  9. Flores-Mateo G, Carrillo-Santisteve P, Elosua R, Guallar E, Marrugat J, Bleys J, et al. Antioxidant enzyme activity and coronary heart disease: meta-analyses of observational studies. Am J Epidemiol. 2009; 170:135-147.

  10. Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J. 1985;110:1100-1107.

  11. Millán J, Pintó X, Muñoz A, Zúñiga M, Rubiés-Prat J, Pallardo LF, et al. Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag. 2009;5:757-765.

  12. Kunutsor SK, Zaccardi F, Karppi J, Kurl S, Laukkanen JA. Is high serum LDL/HDL cholesterol ratio an emerging risk factor for sudden cardiac death? Findings from the KIHD Study. J Atheroscler Thromb. 2017; 24:600-608.

  13. Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zúñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):122.

  14. Londoño-Pérez C, Rodríguez-Rodríguez I, Gantiva-Diaz CA, et al. Cuestionario para la clasificación de consumidores de cigarrillo (C4) para jóvenes. Perspect Psicol. 2011;7:281-291.

  15. Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. AUDIT. The alcohol use disorders identification test. Guidelines for use in primary care. Suiza: World Health Organization/Department of Mental Health and Substance Dependence; 2001.

  16. Levy JC, Matthews D, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21:2191-2192.

  17. López-González ÁA, Rivero-Ledo YI, Vicente-Herrero MT, Gil-Llinás M, Tomás-Salvá M, Riutord-Fe B. Índices aterogénicos en trabajadores de diferentes sectores laborales del área mediterránea española. Clin Investig Arterioscler. 2015;27:118-128.

  18. Kumar S, Batra J, Arora M. Correlation of HDL associated paraoxonase 1 with oxidative stress markers in hypertensive dyslipidemic patients. J Clin Diagnostic Res. 2018;12 BC23-BC26.

  19. Sarhat ER, Sarhat TR. Study of serum levels of melatonin, paraoxonase, oxidative stress in Iraqi patients with acute myocardial infarction. Eur Acad Res. 2016;1:112-131.

  20. Báez-Duarte BG, Zamora-Ginez I, De Jésus KL, Torres-Rasgado E, González-Mejía ME, Porchia L, et al. Association of the metabolic syndrome with antioxidant defense and outstanding superoxide dismutase activity in Mexican subjects. Metab Syndr Relat Disord. 2016;14:154-160.

  21. Rajprabha, Hamid M, KumarMeena R, Syedyawer H. Study of antioxidant enzyme-superoxide dismutase activity and lipid profile in diabetes mellitus patients. Int J Healthc Biomed Res. 2014;2:22-29.

  22. Hisalkar PJ, Patne AB, Fawade MM. Assessment of plasma antioxidant levels in type 2 diabetes patients. Int Biol Med Res. 2012;3:1796-1800.

  23. Humaira M, Raqeeb A, Memon A, Khoharo HK. Malondialdehyde, blood lipids and antioxidant activity in newly diagnosed type 2 diabetics. J Liaquat Uni Med Heal Sci. 2016;15:78-82.

  24. Pioruńska-Stolzmann M, Batko J, Majewski W. Lipid profile, lipase and glutathione peroxidase activities in the serum of patients with atherosclerosis. Med Sci Monit. 1999;5:900-903.

  25. Arthur JR. The glutathione peroxidases. Cell Mol Life Sci. 2001;57:1825-1835.

  26. Yoshida H, Kisugi R. Mechanisms of LDL oxidation. Clin Chim Acta. 2010;411:1875-1882.

  27. Levitan I, Volkov S, Subbaiah PV. Oxidized LDL: diversity, patterns of recognition, and pathophysiology. Antioxid Redox Signal. 2010;13:39-75.

  28. Buijsse B, Lee DH, Steffen L, Erickson RR, Luepker RV, Jacobs DR, et al. Low serum glutathione peroxidase activity is associated with increased cardiovascular mortality in individuals with low HDLc’s. PLoS One. 2012;7 e38901.

  29. Gawlik K, Naskalski JW, Fedak D, Pawlica-Gosiewska D, Grudzień U, Dumnicka P, et al. Markers of antioxidant defense in patients with type 2 diabetes. Oxid Med Cell Longev. 2016;2016:2352361.

  30. Harmon ME, Campen MJ, Miller C, Shuey C, Cajero M, Lucas S, et al. Associations of circulating oxidized LDL and conventional biomarkers of cardiovascular disease in a cross-sectional study of the Navajo population. PLoS One. 2016;11:e0143102.

  31. Huang H, Mai W, Liu D, Hao Y, Tao J, Dong Y. The oxidation ratio of LDL: a predictor for coronary artery disease. Dis Markers. 2008; 24:341-349.

  32. Wang A, Li S, Zhang N, Dai L, Zuo Y, Wang Y, et al. Oxidized low-density lipoprotein to high-density lipoprotein ratio predicts recurrent stroke in minor stroke or transient ischemic attack. Stroke. 2018;49:2637-2642.

  33. Shechter M. Magnesium and cardiovascular system. Magnes Res. 2010;23:1-13.

  34. Kim DJ, Xun P, Liu K, Loria C, Yokota K, Jacobs DR, et al. Magnesium Intake in Relation to Systemic Inflammation, Insulin Resistance, and the Incidence of Diabetes. Diabetes Care. 2010;33:2604-2610.

  35. Chutia H, Lynrah KG. Association of serum magnesium deficiency with insulin resistance in type 2 diabetes mellitus. J Lab Physicians. 2015;7:75-78.

  36. Nasli-Esfahani E, Faridbod F, Larijani B, Ganjali MR, Norouzi P. Trace element analysis of hair, nail, serum and urine of diabetes mellitus patients by inductively coupled plasma atomic emission spectroscopy. J Diabetes Metabol Disord. 2011;10:1-9.

  37. Kimak E, Zięba B, Duma D, Solski J. Myeloperoxidase level and inflammatory markers and lipid and lipoprotein parameters in stable coronary artery disease. Lipids Health Dis. 2018;17:71.

  38. Song P, Xu J, Song Y, Jiang S, Yuan H, Zhang X. Association of plasma myeloperoxidase level with risk of coronary artery disease in patients with type 2 diabetes. Dis Markers. 2015;2015:1-5.

  39. Zubair-Nagi F, Naseem T, Yasmin R. A study of myeloperoxidase and lipid profile in obese individuals. Polish J Manag Stud. 2014;8:726-729.




2020     |     www.medigraphic.com